Shanghai Junshi Biosciences Stock Fundamentals

688180 Stock   29.97  0.13  0.43%   
Shanghai Junshi Biosciences fundamentals help investors to digest information that contributes to Shanghai Junshi's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Junshi's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Junshi stock.
At present, Shanghai Junshi's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 73.9 M, whereas Interest Expense is forecasted to decline to about 19.6 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Shanghai Junshi Biosciences Company Current Valuation Analysis

Shanghai Junshi's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Shanghai Junshi Current Valuation

    
  24.9 B  
Most of Shanghai Junshi's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Junshi Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Shanghai Junshi Biosciences has a Current Valuation of 24.9 B. This is 73.38% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is 49.8% lower than that of the firm.

Shanghai Junshi Bios Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Junshi's current stock value. Our valuation model uses many indicators to compare Shanghai Junshi value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Junshi competition to find correlations between indicators driving Shanghai Junshi's intrinsic value. More Info.
Shanghai Junshi Biosciences is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Junshi by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Junshi's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Shanghai Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Junshi's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Junshi could also be used in its relative valuation, which is a method of valuing Shanghai Junshi by comparing valuation metrics of similar companies.
Shanghai Junshi is currently under evaluation in current valuation category among its peers.

Shanghai Fundamentals

About Shanghai Junshi Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Junshi Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Junshi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Junshi Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue1.5 B1.5 B
Cost Of Revenue667.3 M458.2 M

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

Shanghai Junshi financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Junshi security.